Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 7 October 2025 - 18 October 2025

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 Stockanalysis Marketbeat. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average)…
18 October 2025
···
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close Marketbeat. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating…
16 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026…
16 October 2025
····
MIRA Pharma Stock Skyrockets 100% Overnight as New Pain Drug Outshines Morphine

MIRA Pharma Stock Skyrockets 100% Overnight as New Pain Drug Outshines Morphine

Stock Soars on Breakthrough Announcement MIRA Pharmaceuticals’ stock price skyrocketed overnight on the back of surprising good news. The relatively obscure biotech – which trades on the Nasdaq Capital Market under ticker MIRA – closed Wednesday, Oct. 15 at $1.32 per share Benzinga. That modest close (up less than 1% on the day) gave little hint of what was to…
16 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Stock Performance: Recent Surge and Volatility Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 (Oct 14 close) to $10.42 by Oct 15 close Omeros. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by…
16 October 2025
····
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties…
15 October 2025
···
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies for conditions that currently have none. “We remain fully focused on delivering the first approved therapy for Netherton Syndrome,” said…
11 October 2025
····
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T:…
10 October 2025
····
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today,…
9 October 2025
···
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting the stock to about $14.02 by mid-day Marketbeat Marketbeat. This rally builds on a strong upward trend in recent months…
7 October 2025
····
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Stock Performance & Financial Metrics (as of Oct 7, 2025) Spruce Biosciences’ stock chart for 2025 looks like a hockey stick – mostly flat/down all year and then vertical in October. On Monday, Oct 6, SPRB opened around $8.60 and skyrocketed to $130.40 by the close (+1,378%) after the FDA news. The 52-week high was shattered in the process (previously…
7 October 2025
···
1 … 7 8 9 10

Stock Market Today

  • Zacks Highlights Strong Stock Performers: Amicus, Micron, Amgen Amid Market Uncertainty
    January 19, 2026, 9:46 AM EST. Last week, the Dow, S&P 500, and Nasdaq closed down amid trade-war fears and tariff jitters that pushed investors toward safe havens like gold. Economic and central bank cues remain in focus, with trade negotiations expected to influence market direction. Against this backdrop, Zacks Investment Research spotlights outperforming stocks such as Amicus Therapeutics and Enhabit, which jumped 61.7% and 32.3% respectively following Zacks Rank upgrades. Zacks' equal-weight portfolio of Rank #1 (Strong Buy) stocks outperformed the S&P 500 by 7 percentage points over recent months and the past decade, showing the effectiveness of their stock-rating system. Additional upgraded stocks like Drilling Tools International and Kennametal gained over 20%, indicating strong momentum despite broader market pressures. Investors watch Zacks guidance amid ongoing economic uncertainty to better position portfolios.
Go toTop